Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Inflammatory myofibroblastic tumour (IMT), drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
How long to continue ALK inhibition in children with complete response, and whether surgery after response can allow stopping.
The fusion-negative minority: RNA sequencing to find drivers.
Rare aggressive epithelioid variants that develop resistance mutations to sequential ALK inhibitors.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
ALK-positive inflammatory myofibroblastic tumour
FDA, 14 July 2022, adults and children aged 1 year and older.
Schöffski and colleagues, Lancet Respir Med: high response rate in ALK-positive IMT.
Butrynski and colleagues, NEJM case report.
Griffin and colleagues identify 2p23 rearrangements, the first ALK fusions outside lymphoma.